Amazon Rainforest image with decorative swoopNapo EU logo in white

Presenting Napo EU S.p.A.

Bringing crofelemer to the European market

Amazon Rainforest image with decorative swoop

Presenting Napo EU S.p.A.

Bringing crofelemer to the European market

Napo EU logo in white

About Napo EU

Napo EU S.p.A. is focused on developing crofelemer for the European market. Napo EU is the Italian subsidiary of Napo Pharmaceuticals, a commercial-stage pharmaceutical company based in San Francisco, California, that markets crofelemer in the US and is a wholly owned subsidiary of Jaguar Health. Napo Pharmaceuticals’ focus is on developing and commercializing novel, plant-based, sustainably derived prescription medicines for people with life-altering gastrointestinal (GI) distress—specifically chronic GI malabsorption or debilitating volume and frequency of GI output.

About Napo EU

Napo EU S.p.A. is focused on developing crofelemer for the European market. Napo EU is the Italian subsidiary of Napo Pharmaceuticals, a commercial-stage pharmaceutical company based in San Francisco, California, that markets crofelemer in the US and is a wholly owned subsidiary of Jaguar Health. Napo Pharmaceuticals’ focus is on developing and commercializing novel, plant-based, sustainably derived prescription medicines for people with life-altering gastrointestinal (GI) distress—specifically chronic GI malabsorption or debilitating volume and frequency of GI output.

Arrow icon in white circle
Arrow icon in white circle

Lead crofelemer indication targets

Lead crofelemer indication targets

Napo EU’s initial focus is to pursue conditional marketing authorization from the European Medicines Agency for crofelemer for an important orphan-designated disease: Short bowel syndrome with intestinal failure (SBS-IF).

Napo EU’s initial focus is to pursue conditional marketing authorization from the European Medicines Agency for crofelemer for an important orphan-designated disease: Short bowel syndrome with intestinal failure (SBS-IF).

Arrow icon in white circle
Arrow icon in white circle

Follow-on indication targets for the European market

Follow-on indication targets for the European market

Additional indications being investigated for crofelemer include:

  • HIV-related diarrhea
  • Cancer therapy–related diarrhea (currently being evaluated in a pivotal Phase 3 clinical trial in the US)
  • Congenital diarrheal disorders (CDD)

In addition, there are several other potential diarrheal indications for crofelemer under consideration that could extend the pipeline:

  • Irritable bowel syndrome—diarrhea predominant (IBS-D)*
  • Idiopathic/functional diarrhea*
  • Supportive care for inflammatory bowel disease (IBD)*

Additional indications being investigated for crofelemer include:

  • HIV-related diarrhea
  • Cancer therapy–related diarrhea (currently being evaluated in a pivotal Phase 3 clinical trial in the US)
  • Congenital diarrheal disorders (CDD)

In addition, there are several other potential diarrheal indications for crofelemer under consideration that could extend the pipeline:

  • Irritable bowel syndrome—diarrhea predominant (IBS-D)*
  • Idiopathic/functional diarrhea*
  • Supportive care for inflammatory bowel disease (IBD)*
*U.S. investigator-initiated trial (IIT) sponsored by Napo Pharmaceuticals

News & Resources

News & Resources

Learn more about recent news and upcoming events, and access additional resources for our lead indications

Napo EU logo in white

November 1, 2021

The Merger of Dragon SPAC S.p.A. and Napo EU S.p.A. has Closed

Napo EU logo in white

September 30, 2021

Jaguar Health’s Founder and CEO Lisa Conte to Be Honored with Pure Earth Impact Award

Napo EU logo in white

September 16, 2021

Jaguar Health to Host Investor Webcast Monday, September 20th at 8:30 AM Eastern Time